上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话：021-61312973　　传真：021-55068248
网址：www.shyuanye.com
邮箱：shyysw@sina.com

产品名称：RI-2
产品别名：RI-2

生物活性：

Description	RI-2 is a reversible RAD51 inhibitor, with an IC_{50} of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.
IC_{50} & Target	IC50: 44.17 μM (RAD51)[1]
In Vitro	RI-2 (7a) is a reversible RAD51 inhibitor, with an IC_{50} of 44.17 μM. RI-2 specifically inhibits homologous recombination repair in human cells. RI-2 (150 μM) induces a significant sensitization of cells[1].

Solvent&Solubility

In Vitro:

DMSO : 15.5 mg/mL (35.77 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3080 mL	11.5399 mL	23.0798 mL
	5 mM	0.4616 mL	2.3080 mL	4.6160 mL
	10 mM	0.2308 mL	1.1540 mL	2.3080 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

References	[1]. Budke B, et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10;56(1):254-63.

实验参考：

Cell Assay	HEK293 cells are plated into 96-well tissue culture plates at a density of 300 cells per well in the presence or absence of 50 nM mitomycin C (MMC) for 24 hours at 37°C, 5% CO_2. Media is subsequently replaced with fresh media containing 0.5% DMSO plus RI-2 for an additional 24 hours. RI-2 is then removed, and cultures are allowed to grow to a 50-70% confluence. Average survival from at least three replicates is measured using CellGlo reagentor. RI-2 is deemed successful in sensitizing cells to MMC if they generate significantly greater toxicity in the presence of MMC relative to the absence of MMC. Specifically, sensitization is scored as a "+" when non-overlapping standard errors are observed for at least two pairs of compound doses[1].
References	[1]. Budke B, et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10;56(1):254-63.